Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment

International Clinical Psychopharmacology

Volumn 22, Issue 5, 2007, Pages 249-267

  Carlo Altamura, A ^a   Bobo, William V ^b   Meltzer, Herbert Y ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; Outcome; Relapse; Schizophrenia; Treatment resistance

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPAZINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; HALOPERIL; LAMOTRIGINE; LEPTOPSIQUE; LITHIUM; LOXAPINE; LOXAPINE SUCCINATE; MESORIDAZINE; MESORIDAZINE BESYLATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TOPIRAMATE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADJUVANT THERAPY; ANXIETY DISORDER; BRAIN DAMAGE; CARDIOMYOPATHY; CLINICAL TRIAL; COGNITION; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; LONG TERM CARE; MONOTHERAPY; MORTALITY; MYOCARDITIS; ONSET AGE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; PSYCHOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; SUDDEN DEATH; SUICIDE; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CAUSE OF DEATH; DRUG RESISTANCE; HUMANS; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE; TREATMENT OUTCOME;

EID: 34547760944     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3280de2c7f     Document Type: Review

References (225)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235.
2. Allebeck P (1989). Schizophrenia: a life shortening disease. Schizophr Bull 15:81-89.
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
4. Altamura AC (1992). A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. Schizophr Res 8:187-198.
5. Altamura AC, Curry SH, Montgomery S, Wiles DH (1985). Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology 87:30-33.
6. Altamura AC, Boin F, Maes M (1999). HPA axis and cytokines dysregulation in schizophrenia: potential implications for antipsychotic treatment. Eur Neuropsychopharmacol 10:1-4.
7. Altamura AC, Bassetti R, Sassella F, Salvadori D, Mundo E (2001). Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res 52:29-36.
8. Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E (2003). Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 60:47-55.
9. Altamura C, Guercetti G, Percudani M (1989). Dexamethasone suppression test in positive and negative schizophrenia. Psychiatry Res 30:69-75.
10. American Diabetes Association (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601.
11. Amminger GP, Edwards J, Brewer WJ, Harrigan S, McGorry PD (2002). Duration of untreated psychosis and cognitive deterioration in first episode schizophrenia. Schizophr Res 54:223-230.
12. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. (2005). A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66:63-72.
13. Atbasoglu E, Schultz SK, Andreasen NC (2001). The relationship of akathisia with suicidality and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci 13:336-341.
14. Axelsson R, Lagerkvist-Briggs M (1992). Factors predicting suicide in psychotic patients. Eur Arch Psychiatry Clin Neurosci 241:259-266.
15. Baptista T, Kin NM, Beaulieu S, de Baptista EA (2002). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205-219.
16. Barak Y, Mirecki I, Knobler HY, Natan Z, Aizenberg D (2004). Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology 175:215-219.
17. Barnes TRE, McEvedy CJB (1996). Pharmacological treatment strategies in the nonresponsive schizophrenic patient. Int Clin Psychopharmacol 11:67-71.
18. Basan A, Kissling W, Leucht S (2004). Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr Res 70:33-37.
19. Beasley CM Jr, Tollefson GD, Tran PV (1997). Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 58 (Suppl 10):7-12.
20. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN (2001). The QT interval. Prog Cardiovasc Dis 43:1-45.
21. Bergman RN, Ader M (2005). Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 66:504-514.
22. Bhana N, Foster RH, Olney R, Plosker GL (2001). Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61:111-161.
23. Bhatia MS, Aggarwal NK, Aggarwal BB (2000). Psychosocial profile of suicide ideators, attempters and completers in India. Int J Soc Psychiatry 46:155-163.
24. Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, et al. (2004). Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:173-180.
25. Black KK, Peters L, Rui Q, Milliken H, Whitehorn D, Kopala LC (2001). Duration of untreated psychosis preducts treatment outcome in an early psychosis program. Schizophr Res 47:215-222.
26. Bland RC, Orn H (1980). Prediction of long-term outcome from presenting symptoms in schizophrenia. J Clin Psychiatry 41:85-88.
27. Bleuler M (1976). An approach to a survey of research results on schizophrenia. Schizophrenia Bulletin 2:356-357.
28. Bottlender R, Sato T, Jager M, Wegener U, Wittmann J, Strauss A, Moller HJ (2003). The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res 62:37-44.
29. Bowie CR, Harvey PD (2005). Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 28:613-633.
30. Breier A, Hamilton SH (1999). Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 45:73-77.
31. Bromet EJ, Naz B, Fochtmann LJ, Carlson GA, Tanenberg-Karant M (2005). Long-term diagnostic stability and outcome in recent first-episode cohort studies of schizophrenia. Schizophr Bull 31:639-649.
32. Brooks JO (2001). Successful outcome using quetiapine in a case of treatmentresistant schizophrenia with assaultive behavior. Schizophr Res 50:133-134.
33. Brown S (1997). Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171:502-508.
34. Brown S, Birtwistle J, Roe L, Thompson C (1999). The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701.
35. Brown S, Inskip H, Barraclough B (2000). Causes of the excess mortality in schizophrenia. Br J Psychiatry 177:212-217.
36. Caldwell CB, Gottesman II (1990). Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16:571-589.
37. Casey DE (1991). Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4:109-120.
38. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW (2003). The effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28:182-192.
39. Caton CLM, Showlong PK, Fleiss JL, Koh SP, Barrow S, Goldstein JM (1985). Rehospitalization in chronic schizophrenia. J Nerv Ment Dis 173:139-148.
40. Christison GW, Kirch DG, Wyatt RJ (1991). When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 17:217-245.
41. Cohen D (2004). Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 37:1-11.
42. Cohn TA, Sernyak MJ (2006). Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 51:492-501.
43. Conley RR (1998). Optimizing treatment with clozapine. J Clin Psychiatry 59 (Suppl 3):44-48.
44. Conley RR, Buchanan RW (1997). Evaluation of treatment-resistant schizophrenia. Schizophr Bull 23:663-674.
45. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. (1996). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 155:914-920.
46. Conley RR, Kelly DL, Love RC, McMahon RP (2003a). Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 15:23-31.
47. Conley RR, Kelly DL, Richardson C, Tamminga CA, Carpenter WT Jr (2003b). The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 23:582-594.
48. Conley RR, Kelly DL, Nelson MW, Richardson CM, Feldman S, Benham R, et al. (2005). Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol 28:163-168.
49. Coyle JT (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3:241-253.
50. Cradock-O'Leary J, Young AS, Yano EM, Wang M, Lee ML (2002). Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv 53:874-878.
51. Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N (2000). Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 157:60-66.
52. Csernansky JG, Schuchart EK (2002). Prediction of long-term outcome from presenting symptoms in schizophrenia. J Clin Psychiatry 41: 85-88.
53. Csernansky JG, Mahmoud R, Brenner R (2002). A comparison of rispieridone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22.
54. Davis JM, Matalon L, Watanabe MD, Blake L, Matalon L (1994). Depot antipsychotic drugs. Place in therapy. Drugs 47:741-773.
55. Davis JM, Chen N (2005). Old versus new: weighing the evidence between the first- and second-generation antipsychotics. Eur Psychiatry 20:7-14.
56. Dixon L, Weiden P, Delahanty J, et al. (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903-912.
57. Dixon LB, Lehman AF, Levine J (1995). Conventional antipsychotic medications for schizophrenia. Schizophr Bull 21:567-577.
58. Doering S, Muller E, Kopke W, Pietzcker A, Gaebel W, Linden M, et al. (1998). Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 24:87-98.
59. Dolder CR, Lacro JP, Leckband S, Jeste DV (2003). Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacology 23:389-399.
60. Drici MD, Wang WX, Liu X, Woosley RL, Flockhart DA (1998). Prolongation of QT interval in isolated feline heart by antipsychotic drugs. J Clin Psychopharmacol 18:477-481.
61. Druss BG, Rosenheck RA (1997). Use of medical services by veterans with mental disorders. Psychosomatics 38:451-458.
62. Dursun SM, Gardner DM, Bird DC, Flinn J (1999). Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Can J Psychiatry 44:701-704.
63. Emsley RA, Raniwalla J, Bailey PJ, Jones AM (2000). A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 15:121-131.
64. Ernst CL, Goldberg JF (2004). Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 12:14-41.
65. Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L (1996). Clozapine eligibility among state hospital patients. Schizophr Bull 22:15-25.
66. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64:1250-1257.
67. Flyckt L, Mattsson M, Edman G, Carlsson R, Cullberg J (2006). Predicting 5-year outcome in first-episode psychosis: construction of a prognostic rating scale. J Clin Psychiatry 67:916-924.
68. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
69. Frances A, Docherty JP, Kahn DA (1996). Consensus guideline series: treatment of schizophrenia. J Clin Psychiatry 572:11-50.
70. Fuller MA, Sajatovic M (2005). Drug Information Handbook for Psychiatry. 5th ed. Hudson, OH (USA): Lexi-Comp Inc.
71. Gerlach J (1995). Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 9 (Suppl 5):17-20.
72. Gerlach J (2002). Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 14:47-57.
73. Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ (2005). Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectr 10:1-13.
74. Glassman AH (2005). Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 66 (Suppl 6):5-10.
75. Glassman AH, Bigger JT (2001). Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158:1774-1782.
76. Glick ID, Zaninelli R, Hsu C, Young FK, Weiss L, Gunay I, Kumar V (2004). Patterns of concomitant psychotropic medication use during a 2 year study comparing clozapine and olanzapine for the prevention of suicidal behavior. J Clin Psychiatry 65:679-685.
77. Goldman LS (1999). Medical illness in patients with schizophrenia. J Clin Psychiatry 60:10-15.
78. Green AI, Canuso CM, Brenner MJ, Wojcik JD (2003). Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 26:115-139.
79. Gury C, Canceil O, Iaria P (2000). Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 26:62-72.
80. Guy W, editor. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; (1976). DHEW Publication No. (ADM) 76-338.
81. Haddad PM, Anderson IM (2002). Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62:1649-1671.
82. Harris EC, Barraclough B (1997). Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 170:205-228.
83. Harris EC, Barraclough B (1998). Excess mortality of mental disorder. Br J Psychiatry 173:11-53.
84. Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, et al. (2005). The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 79:85-93.
85. Haro JM, Eaton WW, Bilker WB, Mortensen PB (1994). Predictability of rehospitalization for schizophrenia. Eur Arch Psychiatry Clin Neurosci 244: 241-256.
86. Havaki-Kontaxaki BJ, Ferentinos PP, Kontaxakis VP, Paplos KG, Soldatos CR (2006). Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol 29:52-56.
87. Hector RI (1998). The use of clozapine in the treatment of aggressive schizophrenia. Can J Psychiatry 43:466-472.
88. Henderson DC (2002). Atypical antipsychotics-induced diabetes mellitus: how strong is the evidence? CNS Drugs 16:77-89.
89. Hennekens CH, Hennekens AR, Hollar D, Casey DE (2005). Schizophrenia and increased risks of cardiovascular disease. Am Heart J 150:1115-1121.
90. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG (2004). Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res 68:1-9.
91. Ho BC, Alicata D, Ward J, Moser DJ, O'Leary DS, Arndt S, Andreasen NC (2003). Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry 160:142-148.
92. Hoff AL, Sakuma M, Razi K, Heydebrand G, Csernansky JG, DeLisi LE (2000). Lack of association between duration of untreated psychosis and severity of cognitive and structural brain deficits at the first episode of schizophrenia. Am J Psychiatry 157:1824-1828.
93. Hogarty GE (1993). Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 54 (Suppl):18-23.
94. Hogarty GE, Ulrich RF (1998). The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contribution of psychosocial treatment. J Psychiatr Res 32:243-250.
95. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al.; Clozapine and Risperidone Enhancement (CARE) Study Group (2006). Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354:472-482.
96. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM (2003). Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 15:33-48.
97. Inskip HM, Harris EC, Barraclough B (1998). Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 172:35-37.
98. Jackson C, Birchwood M (1996). Early intervention in psychosis: opportunities for secondary prevention. Br J Clin Psychol 35 (Pt 4):487-502.
99. Jin H, Meyer JM, Jeste DV (2004). Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 71:195-212.
100. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA (2005). Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162:130-136.
101. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen S, Hargreaves WA (1995). Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 46:801-806.
102. Kales HC, Dequardo JR, Tandon R (1999). Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 23:547-556.
103. Kane JM, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
104. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132.
105. Kawachi I (1999). Physical and psychological consequences of weight gain. J Clin Psychiatry 60 (Suppl 21):5-9.
106. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
107. Keith SJ, Kane JM (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64:1308-1315.
108. Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr (2003). Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry 15: 181-186.
109. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM (2006). Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q 77:81-95.
110. Kent S, Yellowlees P (1994). Psychiatric and social reasons for frequent hospitalization. Hosp Community Psychiatry 45:347-350.
111. Kho KH, Blansjaar BA, de Vries S, Babuskova D, Zwinderman AH, Linszen DH (2004). Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia: an open label study. Eur Arch Psychiatry Clin Neurosci 254:372-379.
112. Kim CH, Jayathilake K, Meltzer HY (2003). Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr Res 60:71-80.
113. Kinon BJ, Kane JM, Johns C, Petrovich R, Ismi M, Koreen A, Weiden P (1993). Treatment of neuroleptic-resistant schizophrenic relapse. Psychopoharmacol Bull 29:309-314.
114. Kinon BJ, Ahl J, Stauffer VL, Hill AL, Buckley PF (2004). Dose response and atypical antipsychotics in schizophrenia. CNS Drugs 18:597-616.
115. Klein DF, Davis JM (1969). Diagnosis and drug treatment of psychiatric disorders. Baltimore, MD: Williams & Wilkins.
116. Knapp M (2000). Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl 47:15-18.
117. Kohler CG, Lallart EA (2002). Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep 4:273-278.
118. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK (2005). Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 20:409-415.
119. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, Heresco-Levy U (2004). Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 56:441-446.
120. Kreyenbuhl JA, Kelly DL, Conley RR (2002). Circumstances of suicide among individuals with schizophrenia. Schizophr Res 58:253-261.
121. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, et al. (1995). Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152:179-182.
122. Kupchik M, Spivak B, Mester R, Reznik I, Gonen N, Weizman A, Kotler M (2000). Combined electroconvulsive-clozapine therapy. Clin Neuropharmacol 23:14-16.
123. Lambert T, Velakoulis D, Pantelis C (2003). Medical comorbidity in schizophrenia. MJA 178 (Suppl 9):67-70.
124. Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, et al. (2004). Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 65: 702-706.
125. Lawrence D, Jablensky A, Holman C, Pinder T (2000). Mortality in Western Australian psychiatric patients. Soc Psychiatry Psychiatr Epidemiol 35: 341-347.
126. Leal A, Rosillon D, Mehnert A, Jarema M, Remington G (2004). Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Safety 13:811-816.
127. Lee MA, Jayathilake K, Meltzer HY (1999). A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neurolepticresponsive schizophrenia. Schizophr Res 37:1-11.
128. Lee MA, Thompson PA, Meltzer HY (1994). Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55 (Suppl B):82-87.
129. Lehman AF, Herron JD, Schwartz RP, Myers CP (1993). Rehabilitation for adults with severe mental illness and substance use disorders. A clinical trial. J Nerv Ment Dis 181:86-90.
130. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. (2004a). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 30:193-217.
131. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreybuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines (2004b). Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 161 (2 Suppl):1-56.
132. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68.
133. Leucht S, McGrath J, White P, Kissling W (2002). Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev 2:CD001258.
134. Leucht S, McGrath J, Kissling W (2003). Lithium for schizophrenia. Cochrane Database Syst Rev 3:CD003834.
135. Levinson DF, Umapathy C, Musthaq M (1999). Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 156: 1138-1148.
136. Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S (1998). The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol 18 (2 Suppl 1):20-24.
137. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al., the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs with chronic schizophrenia. N Engl J Med 353:1209-1223.
138. Lindstrom E, Eriksson B, Hellgren A, von Knorring L, Eberhard G (1995). Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 17:402-412.
139. Lykestos CG, Dunn G, Kaminsky MJ, Breakey WR (2002). Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics 43:24-30.
140. Marder SR (2003). Overview of partial compliance. J Clin Psychiatry 64 (Suppl 16):3-9.
141. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. (2002). The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 28:5-16.
142. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334-1349.
143. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 62: 975-983.
144. Mason P, Harrison G, Glazebrook C, Medley I, Croudace T (1996). The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISoS) coordinated by the World Health Organization. Br J Psychiatry 169:580-586.
145. McEwen BS (2000). Effects of adverse experiences for brain structure and function. Biol Psychiatry 48:721-731.
146. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al.; CATIE Investigators (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610.
147. McKee HA, D'Arcy PF, Wilson PJ (1986). Diabetes and schizophrenia: a preliminary study. J Clin Hosp Pharm 11:297-299.
148. Meltzer HY (1997). Treatment-resistant schizophrenia: the role of clozapine. Curr Med Res Opin 14:1-20.
149. Meltzer HY (1999). Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. J Clin Psychiatry 60 (Suppl 12):47-50.
150. Meltzer HY (2001). Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 932:44-60.
151. Meltzer HY, Bobo WV (2006). Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectrums 11 (7 Suppl 7):14-24.
152. Meltzer HY, Okayli G (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152:183-190.
153. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003a). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
154. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al., InterSePT Study Group (2003b). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82-91.
155. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Yagcioglu EA, Small J (2007). A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry [in press].
156. Meyer JM, Nasrallah HA, editors. (2003). Medical illness and schizophrenia. Washington, DC: American Psychiatric Publishing, Inc.
157. Moller HJ (2003). Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 17:793-823.
158. Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olie JP, et al. (2006). Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol 29:28-33.
159. Mukherjee S, Roth S, Sandyk R (1989). Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Res 29:17-27.
160. Mukherjee S, Decina P, Bocola V (1996). Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68-73.
161. Muller N (2004). Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 37 (Suppl 2):S141-S147.
162. Muller-Siecheneder F, Muller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O (1998). Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 18:111-120.
163. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1): 1-93.
164. Nordentoft M, Laursen TM, Agerbo E, Qin P, Hoyer EH, Mortensen PB (2004). Change in suicide rates for patients with schizophrenia in Denmark, 1981-97: nested case-control study. BMJ 329:261.
165. Norman RM, Lewis SW, Marshall M (2005). Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry Suppl 48:S19-S23.
166. Oehl M, Hummer M, Fleischhacker WW (2000). Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 407:83-86.
167. Olfson M, Mechanic D, Boyer CA, Hansell S, Walkup J, Weiden PJ (1999). Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis 187:721-729.
168. Olney JW, Farber NB (1995). Glutamater receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
169. Palmer BA, Pankratz VS, Bostwick JM (2005). The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 62:247-253.
170. Palmer DD, Henter ID, Wyatt RJ (1999). Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry 60 (Suppl 2):100-103.
171. Pantelis C, Lambert T Jr (2003). Managing patients with treatment-resistant schiziphrenia. MJA 178:62-66.
172. Perkins DO, Gu H, Boteva K, Lieberman JA (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162:1785-1804.
173. Rampe D, Murawsky MK, Grau J, Lewis EW (1998). The antipsychotics agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286:788-793.
174. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT (2001). Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 58:1161-1167.
175. Reid WH, Mason M, Hogan T (1998). Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 49:1029-1033.
176. Reilly JG, Ayis SA, Ferrier IN, Jones ST, Thomas HL (2000). QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048-1052.
177. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA (1990). Costeffectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 41:850-854.
178. Reynolds K, He J (2005). Epidemiology of the metabolic syndrome. Am J Med Sci 330:273-279.
179. Reznik I, Benatov R, Sirota P (1996). Seroquel in a resistant schizophrenic with negative and positive symptoms. Harefuah 130:675-677, 727.
180. Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 68:29-39.
181. Ripoll N, Bronnec M, Bourin M (2004). Nicotinic receptors and schizophrenia. Curr Med Res Opin 20:1057-1074.
182. Rivara FP, Ebel BE, Garrison MM, Christakis DA, Wiehe SE, Levy DT (2004). Prevention of smoking-related deaths in the United States. Am J Prev Med 27:118-125.
183. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241-247.
184. Rosen K, Garety P (2005). Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull 31:735-750.
185. Rund BR, Melle I, Friis S, Larsen T, Midboe LJ, Opjordsmoen S, et al. (2004). Neurocognitive dysfunction in first episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry 161:466-472.
186. Sacco KA, Bannon KL, George TP (2004). Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 18:457-474.
187. Schooler NR (2003). Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 64 (Suppl 16):14-17.
188. Shader RI, Greenblatt DJ (1998). Potassium, antipsychotic agents, arrhythmias, and sudden death. J Clin Psychopharmacol 18:427-428.
189. Shepherd M, Watt D, Falloon I, Smeeton N (1989). The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl 15: 1-46.
190. Sheitman BB, Lieberman JA (1998). The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res 32:143-150.
191. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. (1997). Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 171:569-573.
192. Siris SG (2000). Depression in schizophrenia: perspective in the era of 'Atypical' antipsychotic agents. Am J Psychiatry 157:1379-1389.
193. Siris SG (2001). Suicide and schizophrenia. J Psychopharmacol 15:127-135.
194. Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, et al. (1998). Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 21: 245-250.
195. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang AF, Busch AE (1997). The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channel expressed in Xenopus oocytes. Br J Pharmacol 120: 968-974.
196. Sullivan G, Wells KB, Morgenstern H, Leake B (1995). Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 152:1749-1756.
197. Swanson JW, Swartz MS, Elbogen EB (2004). Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull 30:3-20.
198. Szigethy E, Brent S, Findling RL (1998). Quetiapine for refractory schizophrenia. J Am Acad Child Adolesc Psychiatry 37:1127-1128.
199. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM (1994). Clozapine in tardive dyskinesia: observation from human and animal model studies. J Clin Psychiatry 55:102-106.
200. Tapp A, Kilzieh N, Wood AE, Raskind M, Tandon R (2001). Depression in patients with schizophrenia during an acute psychotic episode. Compr Psychiatry 42:314-318.
201. Tattan TM, Creed FH (2001). Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 27:149-155.
202. Taylor DM, McAskill R (2000). Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 101:416-432.
203. Tharyan P, Adams CE (2005). Elelctroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2:CD000076.
204. Theberge J, Al-Semaan Y, Drost DJ, Malla AK, Neufeld RW, Bartha R, et al. (2004). Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla. Psychiatry Res 131:107-114.
205. Thomas SHL (1994). Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev 13:77-102.
206. Tiihonen J, Hallikainen T, Ryynanen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, et al. (2003). Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54:1241-1248.
207. Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, et al. (2005). Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 66:1012-1015.
208. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia Study Group (2001). Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 49:52-63.
209. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407-418.
210. Tranulis C, Mouaffak F, Chouchana L, Stip E, Gourevitch R, Poirier MF, et al. (2006). Somatic augmentation strategies in clozapine resistance: what facts? Clin Neuropharmacol 29:34-44.
211. Tulloch AD, Fearon P, David AS (2006). Social outcomes in schizophrenia: from description to action. Curr Opin Psychiatry 19:140-144.
212. Van Os J, Altamura AC, Bobes J, Gerlach J, Hellewell JSE, Kasper S, et al. (2004). Evaluation of the two-way communication checklist as a clinical intervention. Br J Psychiatry 184:79-83.
213. Van Putten T, Marder SR (1987). Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 48 (Suppl):13-19.
214. Volavka J (1999). The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry 60 (Suppl 12):43-46.
215. Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R (2000). Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry 24:911-922.
216. Walker AM, Lanza LL, Arellano F, Rothman KJ (1997). Mortality in current and former users of clozapine. Epidemiology 8:671-677.
217. Weickert TW, Goldberg TE (2005). First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep 7:304-310.
218. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R (1998). Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 24:75-85.
219. Winkour G, Tsuang M (1975). The Iowa 500: suicide in mania, depression, and schizophrenia. Am J Psychiatry 132:650-651.
220. Wirshing DA, Marshall BD, Green MF, Mintz J, Marder SR, Wirshing WC (1999). Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 156: 1374-1379.
221. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457-472.
222. Wyatt RJ (1991). Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 5:201-202.
223. Wyatt RJ (1995). Early intervention for schizophrenia: can the course of the illness be altered? Biol Psychiatry 38:1-3.
224. Zareba W, Lin DA (2003). Antipsychotic drugs and QT interval prolongation. Psychiatr Q 74:291-306.
225. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC (2001). Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol 16:325-330.